MUC5AC
ENSG00000215182
Target class
Secreted protein
Chromosome
11
Approved drugs
0
Clinical candidates (approved and in development)
3
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- MUC5
- Target name
- MUC5AC
- Gene name
- Mucin 5AC, oligomeric mucus/gel-forming
- Gene symbol
- MUC5AC
- Protein name
- Mucin-5AC (MUC-5AC) (Gastric mucin) (Major airway glycoprotein) (Mucin-5 subtype AC, tracheobronchial) (Tracheobronchial mucin) (TBM)
- Gene biotype
- Protein coding
- Gene family
- Mucins
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 1
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 132.81
- Tissue specificity (Gini)
- 0.977
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:4586
- Protein interaction confidence
- 0.820167
- Protein interaction partners
- 30
- R-HSA-5083625
- R-HSA-5083632
- R-HSA-5083636
- R-HSA-5621480
- R-HSA-913709
- R-HSA-977068
- End position
- 1201138
- Start position
- 1157953
- Chromosome
- 11
- Strand
- Forward
- Secreted .
- PubMed 14718370
- PubMed 31732694
- Tissue specificity (tau)
- 0.999805
- Expression inequality (Gini)
- 0.977109
Expression in transcripts per million
- Stomach
- 132.81
- Testis
- 0.32
- Lung
- 0.12
- Cervix - Endocervix
- 0.1
- Minor Salivary Gland
- 0.07
Expression in transcripts per million
- Stomach132.81
- Testis0.32
- Lung0.12
- Cervix - Endocervix0.1
- Minor Salivary Gland0.07
- Prostate0.06
- Cervix - Ectocervix0.05
- Fallopian Tube0.05
- Pituitary0.03
- Uterus0.03
- Colon - Transverse0.03
- Vagina0.03
- Bladder0.03
- Esophagus - Mucosa0.02
- Small Intestine - Terminal Ileum0.02
- Pancreas0.02
- Spleen0.02
- Cells - EBV-transformed lymphocytes0.02
- Ovary0.02
- Esophagus - Gastroesophageal Junction0.02
- Artery - Aorta0.02
- Brain - Cerebellum0.02
- Adrenal Gland0.02
- Liver0.01
- Esophagus - Muscularis0.01
And 29 more, listed on the interactive page.
- GO:0005576
- GO:0005796
- GO:0005886
- GO:0070062
- GO:0070701
Molecular functions
- GO:0005201
Related records
Trials (8)
- A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
- A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
- Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
- QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
- QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
- Safety and Efficacy Study of 90Y-hPAM4 at Different Doses
- Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer
Drugs (3)
- Clivatuzumab tetraxetan Mucin-5AC binding agent
- Ensituximab Mucin-5AC other
- Yttrium Y 90 clivatuzumab tetraxetan Mucin-5AC binding agent